Sangui BioTech International Inc.: Personnel Restructuring in SanguiBioTech AG's and GlukoMediTech AG's Supervisory Boards and Board of Managements.

Business Editors

SANTA ANA, Calif.--(BUSINESS WIRE)--May 28, 2001

Sangui BioTech International, Inc., (NASDAQ OTC BB: SGBI; WKN 906 757; SBH.GR (Bloomberg), SGBI.H (Reuters)) announces that its two 100% subsidiaries SanguiBioTech AG and GlukoMediTech AG, both headquartered in Witten, Germany, have restructured the personnel on their Supervisory Boards and Boards of Management.

During special meetings of stockholders held on May 23, 2001 in Witten, for SanguiBioTech AG, Professor Dr. Joachim Lutz, and attorney Dora Malek were nominated to replace two of the former Supervisory Board members. Professor Dietrich Gronemeyer, M.D. and attorney Dora Malek were elected to GlukoMediTech AG's Supervisory Board.

After the general stockholder's meeting held on May 27, 2001 during which the number of Supervisory Board members was increased to six for both German enterprises in accordance with a change in the charter and bylaws, the Supervisory Boards are composed as follows:

SanguiBioTech AG: Chairman of the Supervisory Board: Professor Dr. Joachim Lutz; Deputy Chairperson: Dora Malek; further members: Dr. Oswald Burkhard; Dr. Doris Barnikol-Keuten, Cornelius Grau, businessman; Professor Gronemeyer, M.D.

GlukoMediTech AG: Chairman of the Supervisory Board: Professor Dietrich Gronemeyer, M.D.; Deputy Chairperson: Dora Malek; further members: Dr. Oswald Burkhard; Dr. Doris Barnikol-Keuten; Cornelius Grau, businessman; Professor Dr. Joachim Lutz.

Dr. Dr. Oswald Burkhard, previously a member of the Board of Management of both German companies, resigned from his Board of Management positions and was subsequently elected to the Supervisory Boards. The Supervisory Boards of both enterprises then appointed Dr. Sieglinde Borchert as member to their Boards of Management.

"We have set the course for the future with these personnel changes," expressed company founder Professor Dr. Dr. Wolfgang Barnikol with satisfaction about the restructuring of the executive bodies. "With the expansion of the Supervisory Boards and added business/financial qualifications, as well as legal and additional scientific qualifications of the new members, we are giving both companies further expertise and additional impetus."

Curriculum Vitae of the new members of the Supervising Boards:

Attorney Dora Malek, date of birth 7/26/1957 in Wuppertal, employed since 1990 in the finance department of an international insurance company in the area of group investments, and since 1994 as an independent attorney specializing in banking and stock exchange law, capital investment law and the law of partnerships and corporations. She will aid the company not only in all legal matters, but also in the development of financial and investment concepts.

C. Cornelius Grau, Degree in Business Administration, date of birth 8/19/1955 in Hamburg, since 1990 built up his own corporate group for real estates and corporate holdings, member of several supervisory and advisory boards of investment companies. He will bring expertise in the areas of marketing as well as corporate and market strategies with him to the corporate group.

Professor Joachim Lutz, M.D., date of birth 5/15/1932 in Ludwigshafen, professor and lecturer in medical physiology in the subject area of the vascular system and venous pressure at the Physiological Institute of the Bavarian-Julius-Maximilian University in Wurzburg until his retirement in 1998. There he spent years evaluating artificial oxygen carriers in small animal models such as the magneto metric determination of the impairment of the body's own macrophages that are responsible for detoxification. He is a member of the "International Advisory Committee on Blood Substitutes (ISABI)" as well as the "International Society on Oxygen Transport to Tissue (ISOTT)". He will accelerate development work as well as the pre-clinical and clinical testing of blood with artificial oxygen carriers with his technical knowledge and experience.

Professor Dietrich H. W. Gronemeyer, M.D., date of birth 11/12/1952 in Clausthal-Zellerfeld, internationally known due to his development of micro-therapy, micro-operations with intervertebral disks and tumors as well as the world's first operation on open nuclear spin tomographs (1988). He is a member of numerous internationally known scientific and medical institutions, among them "New York Academy of Sciences", "European Congress of Radiology" and "National Scientific Committee of the World Congress of High-Tech Medicine", Hannover. He established the distinguished international Congress "High Care" in Bochum with an emphasis on high-tech medicine and bringing together physicians, engineers and scientists, which he led as president in 1997 and 2000. In May 2001 he was appointed professor at Georgetown University in Washington D.C. For his overriding scientific and medical achievements he was awarded multiple times with the title of "Man of the Year" and in 1999 as "Man of the Millennium". He will be placing his extraordinary technical knowledge in particular in the area of medical micro-techniques at the disposal of GlukoMediTech AG for development work on implantable glucose sensors.

This news release includes statements, other than historical fact, that may be deemed forward-looking. These statements may be accompanied by words such as "believe," "estimate," "project," "expect," "anticipate," or "predict" that conveys the uncertainty of future events or outcomes. These statements are based on assumptions that the Company believes are reasonable; however, many factors could cause the Company's actual results in the future to differ materially from the forward-looking statements made herein and in any other documents or oral presentations made by, or on behalf of, the Company. Important factors which could cause actual results to differ materially from those in forward-looking statements include, among others, the ability to obtain additional financing, which is not assured; rapid technological developments and changes; problems in developments of the Company's products; price and product competition by competitors; general economic conditions; and factors discussed in the Company's SEC filings.